The AATF (Apoptosis Antagonizing Transcription Factor) antibody is a key tool for studying the multifunctional protein AATF, which plays critical roles in cellular homeostasis, stress response, and cancer biology. AATF, also known as CHE-1 or DED, is a 523-amino acid protein containing conserved domains like the leucine zipper and nuclear localization signals. It regulates apoptosis by interacting with p53. MDM2. and other pro-survival pathways, while also modulating transcription, cell cycle progression, and DNA damage repair.
AATF antibodies (typically rabbit or mouse monoclonal/polyclonal) enable researchers to detect and quantify AATF expression in various experimental models. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, immunofluorescence, and co-immunoprecipitation to investigate AATF's subcellular localization, protein interactions, and expression patterns in normal vs. diseased tissues.
Given AATF's overexpression in cancers (e.g., prostate, breast, glioblastoma) and its links to chemoresistance, AATF antibodies have become essential for exploring its oncogenic mechanisms and therapeutic potential. Commercial AATF antibodies are often validated for specificity using knockout cell lines or siRNA-mediated knockdown. Proper controls, including isotype-matched antibodies and peptide blocking experiments, are recommended to ensure result reliability.